Who are FOSAMAX PLUS D's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Risedronate/Cholecalciferol combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fosamax-plus-d.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

FOSAMAX PLUS D — Competitive Intelligence Brief

FOSAMAX PLUS D (FOSAMAX PLUS D) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate + vitamin D3 combination. Area: Bone metabolism / Osteoporosis.

marketed Bisphosphonate + vitamin D3 combination Osteoclast proton pump (alendronate); vitamin D receptor (cholecalciferol) Bone metabolism / Osteoporosis Small molecule Live · refreshed every 30 min

Target snapshot

FOSAMAX PLUS D (FOSAMAX PLUS D) — Organon and Co. FOSAMAX PLUS D combines alendronate (a bisphosphonate that inhibits bone resorption) with cholecalciferol (vitamin D3) to prevent and treat osteoporosis while ensuring adequate vitamin D status.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FOSAMAX PLUS D TARGET	FOSAMAX PLUS D	Organon and Co	marketed	Bisphosphonate + vitamin D3 combination	Osteoclast proton pump (alendronate); vitamin D receptor (cholecalciferol)
Risedronate/Cholecalciferol combination	Risedronate/Cholecalciferol combination	Hanlim Pharm. Co., Ltd.	marketed	Bisphosphonate + vitamin D3 combination	Osteoclast farnesyl pyrophosphate synthase (risedronate); vitamin D receptor (cholecalciferol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate + vitamin D3 combination class)

Hanlim Pharm. Co., Ltd. · 1 drug in this class
Organon and Co · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FOSAMAX PLUS D — Competitive Intelligence Brief. https://druglandscape.com/ci/fosamax-plus-d. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab